DDInter11 DDInter1435
Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal glucoamylase, sucrase, maltase, and isomaltase - which are responsible for the metabolism of complex starches and oligo-, tri-, and disaccharides into absorbable simple sugars.[L31633,A37868] By inhibiting the activity of these enzymes, acarbose limits the absorption of dietary carbohydrates and the subsequent postprandial increase in blood glucose and insulin levels. Acarbose is therefore used in conjunction with diet, exercise, and other pharmacotherapies for the management of blood sugar levels in patients with type 2 diabetes.[L31628,L31633] Acarbose is one of only two approved alpha-glucosidase inhibitors (the other being
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Acarbose {u} (Compound) resembles {v} (Compound) Amikacin
Acarbose {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Neomycin
Acarbose {u} (Compound) treats {v} (Disease) type 2 diabetes mellitus
Acarbose {u} (Compound) binds {v} (Gene) AMY1B
Acarbose {u} (Compound) upregulates {v} (Gene) PAK1
Acarbose {u} (Compound) is included by {v} (Pharmacologic Class) alpha Glucosidase Inhibitors
Acarbose {u} (Compound) downregulates {v} (Gene) S100A13
Acarbose {u} (Compound) causes {v} (Side Effect) Hepatic function abnormal
Acarbose {u} may cause a minor interaction that can limit clinical effects when taken with {v} Amcinonide
Acarbose {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lipoic acid
Acarbose (Compound) resembles Amikacin (Compound)
Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Neomycin
Acarbose (Compound) treats type 2 diabetes mellitus (Disease)
Acarbose (Compound) binds AMY1B (Gene)
Acarbose (Compound) upregulates PAK1 (Gene)
Acarbose (Compound) is included by alpha Glucosidase Inhibitors (Pharmacologic Class)
Acarbose (Compound) downregulates S100A13 (Gene)
Acarbose (Compound) causes Hepatic function abnormal (Side Effect)
Acarbose may cause a minor interaction that can limit clinical effects when taken with Amcinonide
Acarbose may cause a minor interaction that can limit clinical effects when taken with Lipoic acid